SL
XBI icon

Salomon & Ludwin’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Salomon & Ludwin’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-493
Closed -$46.8K – 839
2024
Q1 		$46.8K Hold
493
– – ﹤0.01% 364
2023
Q4 		$36K Hold
493
– – ﹤0.01% 347
2023
Q3 		$36K Buy
+493
New +$39.4K ﹤0.01% 347

Other funds holding XBI

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Salomon & Ludwin's XBI Position: Q2 2024 in Review

Salomon & Ludwin sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 493 shares — an estimated $46.8K sold.

Salomon & Ludwin first reported a position in XBI in Q3 2023 and held it in 3 quarters. The position peaked at $46.8K in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Salomon & Ludwin reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Salomon & Ludwin sold 493 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $46.8K.
  • Salomon & Ludwin first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and held it in 3 quarters.
  • Salomon & Ludwin's State Street SPDR S&P Biotech ETF position peaked at $46.8K in Q1 2024.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Salomon & Ludwin's 13F filing for Q2 2024, filed 25 Jul 2024.